- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07942363
Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours (LET-PT)
Evaluating Clinical Impact of Linear Energy Transfer Distribution in Proton Therapy for Primary Brain Tumours - a Prospective Study
The goal of this prospective study is to evaluate whether incorporating linear energy transfer (LET) and variable relative biological effectiveness (RBE) into proton therapy (PT) treatment planning is feasible and may reduce treatment-related adverse events in patients with primary brain tumours. For all participants, the LET distribution and the McNamara variable RBE model will be evaluated during treatment planning. Where feasible, the proton therapy plan will be optimised to reduce areas of high LET in healthy brain tissue while maintaining adequate treatment of the tumour. Participants will undergo standard clinical and MRI follow-up and will additionally be asked to complete quality-of-life questionnaires at several time points.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In clinical treatment planning, a constant RBE of 1.1 is assumed. However, proton RBE depends on several factors, including linear energy transfer (LET). RBE uncertainties can result in unexpected toxicities in patients treated with proton therapy (PT) for primary brain tumours. To address RBE uncertainties in PT treatment planning, this prospective trial evaluates the feasibility and outcomes of incorporating LET distribution information and the McNamara variable RBE model into treatment planning for patients diagnosed with primary brain tumours. The primary objective is to evaluate the effect of this planning strategy on the incidence of treatment-related imaging abnormalities (TRIA) in healthy brain tissue after PT. Outcomes will be compared with those of a historical cohort of patients who received PT at the same centre before the introduction of the novel planning strategy.
Secondary objectives are:
- To gain further insight into the feasibility of an LET-based treatment planning method in primary brain tumours.
- To assess additional side effects after PT for primary brain tumours.
- To investigate the response of primary brain tumours after PT.
Participants will undergo standard clinical and MRI follow-up and will complete quality-of-life questionnaires at predefined time points.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lieselotte Lauwens, MD
- Phone Number: +32 16 34 76 00
- Email: lieselotte.lauwens@uzleuven.be
Study Contact Backup
- Name: Maarten Lambrecht, MD PhD
- Phone Number: +32 16 34 76 00
- Email: maarten.lambrecht@uzleuven.be
Study Locations
-
-
-
Leuven, Belgium
- UZ Leuven
-
Contact:
- Maarten Lambrecht, MD PhD
- Phone Number: +32 16 34 76 00
- Email: maarten.lambrecht@uzleuven.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Patients diagnosed with primary brain tumours including, but not limited to:
- Low-grade glioma including: paediatric-type diffuse low-grade glioma, astrocytoma, IDH-mutant and oligodendroglioma, IDH-mutant and 1p/19q-codeleted
- Ependymal tumours
- Tumours of the sellar region including, but not limited to, craniopharyngioma
- Medulloblastoma and other embryonal tumours, including, but not limited to, atypical teratoid/rhabdoid tumours
- Meningioma
- Primary neuroectodermal tumours
- Germ cell tumours
- Choroid plexus tumours
- Pineal tumours
-
Both adults and children are eligible for inclusion
-
Referred to PARTICLE for proton therapy treatment
-
Treatment with PT approved and reimbursed by RIZIV/INAMI
-
Ability of patient and/or parents or legal guardian to sign informed consent
Exclusion Criteria:
- Mixed photon-proton planning
- Re-irradiation
- Contraindication for MRI (claustrophobia, metallic implants like pacemaker/ICD/neurostimulator)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: LET-based evaluation in treatment planning
|
Treatment planning will initially be performed according to standard clinical practice using an RBE-weighted dose based on a fixed RBE of 1.1, expressed in Gy(RBE). The resulting plan will then undergo additional evaluation using LET distributions and variable RBE-weighted dose distributions calculated with the McNamara model. If areas of high LET or high estimated biological dose are identified in healthy brain tissue, the treatment plan may be adjusted to reduce these areas while maintaining adequate target coverage and compliance with standard dose constraints for organs at risk. LET and variable RBE evaluation will be used as auxiliary planning metrics and will not replace standard clinical dose evaluation.
Other Names:
MRI assessments according to routine follow-up for TRIA and response assessment. Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30 and EORTC QLQ-BN20 questionnaires. Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumour Module. Evaluating the incidence of CNS toxicities using the CTCAE v5.0 |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The occurrence of Treatment-Related Imaging Abnormality (TRIA) CTCAE version 5.0 grade ≥ 1.
Time Frame: Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.
|
TRIA is defined as any new or increased abnormality observed on post-contrast T1-weighted, T2-weighted, or T2-weighted-FLAIR MRI sequences, absent on the corresponding pre-radiotherapy (and post-surgical, if surgery preceded radiotherapy) imaging, not consistent with post-surgical changes or unambiguous tumour progression, with confirmation on subsequent follow-up MRI recommended to substantiate this diagnosis. TRIA will be scored as a CNS necrosis adverse event according to the CTCAE scale version 5.0. |
Up to 12 months after treatment. MRI at 6 and 12 months after completion of proton therapy treatment for assessment of TRIA.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment planning feasibility: number of plan iterations.
Time Frame: Baseline (during treatment planning).
|
Evaluating the number of plan iterations required for a satisfactory LET-based treatment plan, acting as a surrogate for additional planning time required in the treatment planning workflow. |
Baseline (during treatment planning).
|
|
Treatment planning feasibility: number of plans requiring LET-based replanning.
Time Frame: Baseline (during treatment planning).
|
Evaluating the number of RBE1.1-based plans in need of a replanning to a LET-based treatment plan. |
Baseline (during treatment planning).
|
|
Treatment planning feasibility: planning effort
Time Frame: Baseline (once before and once after LET-based replanning).
|
Evaluating the effort needed for replanning using the National Aeronautics and Space Administration Task Load Index (NASA-TLX). Workload is rated on six subscales (mental demand, physical demand, temporal demand, performance, effort and frustration), each scored from 0 to 20; the overall score is the mean of the six subscales (0-20). Higher scores indicate a higher workload (worse outcome). |
Baseline (once before and once after LET-based replanning).
|
|
CNS toxicities
Time Frame: Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.
|
Evaluating the incidence of CNS toxicities graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grades range from 1 (mild) to 5 (death related to adverse event); higher grades indicate a worse outcome. |
Baseline; during proton therapy in weeks 1, 2, 3, 4, 5 and 6; and at 3, 6, 9 and 12 months after proton therapy.
|
|
Quality of life assessments: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).
Time Frame: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
Assessing QoL in adults (aged > 25 years) using the EORTC QLQ-C30. Scores range from 0 to 100. For the global health status and functional scales, higher scores indicate better quality of life and functioning; for the symptom scales, higher scores indicate a higher symptom burden (worse outcome). |
Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
|
Quality of life assessments: European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire - Brain Neoplasm (20 items) (EORTC QLQ-BN20).
Time Frame: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
Assessing QoL in adults (aged >25 years) using the EORTC QLQ-BN20. Scores range from 0 to 100; higher scores indicate a higher symptom burden (worse outcome). |
Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
|
Quality of life assessments: Pediatric Quality of Life Inventory (PedsQL) Brain Tumor Module.
Time Frame: Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
Assessing QoL in children (aged ≤ 25 years) using the age-appropriate PedsQL Brain Tumor Module. Scores range from 0 to 100; higher scores indicate better health-related quality of life. |
Baseline; at last proton therapy fraction; 6 and 12 months after proton therapy.
|
|
Response assessment
Time Frame: At 6 and 12 months after proton therapy.
|
Number of participants per response category (complete response, partial response, stable disease, progressive disease) according to the Response Assessment in Neuro-Oncology (RANO) criteria. |
At 6 and 12 months after proton therapy.
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum LETd in healthy brain tissue.
Time Frame: Baseline (after treatment planning).
|
Comparing the maximum dose-averaged linear energy transfer (LETd), reported as D1% (in keV/µm), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum constant RBE-weighted dose in healthy brain tissue.
Time Frame: Baseline (after treatment planning).
|
Comparing the maximum constant RBE-weighted dose (RBE 1.1), reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Maximum variable RBE-weighted dose in healthy brain tissue.
Time Frame: Baseline (after treatment planning).
|
Comparing the maximum McNamara variable RBE-weighted dose, reported as D0.03cc (in Gy(RBE)), in healthy brain tissue between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
|
Comparing RBE1.1-based PT plan and a LET-based treatment plan: Target coverage.
Time Frame: Baseline (after treatment planning).
|
Comparing target coverage, reported as [CTV D98%] (in Gy(RBE)), between the RBE1.1-based plan and the LET-based plan. |
Baseline (after treatment planning).
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Site
- Neoplasms
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Brain Neoplasms
- Therapeutics
- Public Health
- Environment and Public Health
- Health Status
- Demography
- Epidemiologic Measurements
- Heavy Ion Radiotherapy
- Radiotherapy
- Quality of Life
- Proton Therapy
Other Study ID Numbers
- S71405
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.